Adverse

  • CBD NewsPhoto of Lexaria’s DehydraTECH CBD Hypertension Study Dosing Completed Without Serious Adverse Events

    Lexaria’s DehydraTECH CBD Hypertension Study Dosing Completed Without Serious Adverse Events

    Lexaria Bioscience Corp. LEX LEXXW revealed that dosing with Lexaria CBD processed with DehydraTECH is complete in its multi-week human hypertension clinical trial HYPER-H21-4and this no serious adverse events were reported as a result of dosing. HYPER-H21-4 is a randomized, double-blind, placebo-controlled, crossover study designed to enroll a minimum of 60 patients. Dosing has now been completed, meaning that all…

    Read More »
  • CBD NewsPhoto of Lexaria’s DehydraTECH-CBD Hypertension Study HYPER-H21-4 Full Dosing No Serious Adverse Events

    Lexaria’s DehydraTECH-CBD Hypertension Study HYPER-H21-4 Full Dosing No Serious Adverse Events

    KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that dosing with Lexaria’s DehydraTECH™ processed cannabidiol (“DehydraTECH-CBD” “) was completed in its multi-week human hypertension clinical trial HYPER-H21-4 and that no serious dosing-related adverse events were reported. HYPER-H21-4 is a randomized,…

    Read More »
  • CBD NewsPhoto of Lexarias DehydraTECH-CBD Hypertension Study HYPER-H21-4 Full Dosing No Serious Adverse Events

    Lexarias DehydraTECH-CBD Hypertension Study HYPER-H21-4 Full Dosing No Serious Adverse Events

    (via TheNewswire) Kelowna, British Columbia –The Newswire –July 27, 2022 – Lexaria Bioscience Corp.(Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that dosing with Lexaria’s DehydraTECH™ processed cannabidiol (“DehydraTECH-CBD”) was completed in its multi-week human hypertension clinical trial HYPER-H21-4 and that no serious dosing-related adverse events were reported. HYPER-H21-4,was a randomized,…

    Read More »
  • CBD NewsPhoto of Lexaria DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Completed Without Serious Adverse Events

    Lexaria DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Completed Without Serious Adverse Events

    KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that dosing with Lexaria’s DehydraTECH™ processed cannabidiol (“DehydraTECH-CBD” “) was completed in its multi-week human hypertension clinical trial HYPER-H21-4 and that no serious dosing-related adverse events were reported. HYPER-H21-4 is a randomized,…

    Read More »
Back to top button